Stratos Wealth Partners’s AbbVie ABBV Stock Holding History

Stratos Wealth Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$36.6M	Sell	168,351 -7,655	-4%	-$1.7M	0.42%	41
2025 Q4	$40.2M	Sell	176,006 -2,260	-1%	-$515K	0.45%	37
2025 Q3	$41.3M	Buy	178,266 +10,346	+6%	+$2.11M	0.49%	37
2025 Q2	$31.2M	Buy	167,920 +4,820	+3%	+$896K	0.42%	42
2025 Q1	$34.2M	Sell	163,100 -5,019	-3%	-$976K	0.52%	34
2024 Q4	$29.9M	Sell	168,119 -1,261	-0.7%	-$232K	0.42%	40
2024 Q3	$33.4M	Buy	169,380 +11,233	+7%	+$2.1M	0.48%	35
2024 Q2	$27.1M	Sell	158,147 -708	-0.4%	-$117K	0.43%	39
2024 Q1	$28.9M	Sell	158,855 -2,275	-1%	-$392K	0.48%	32
2023 Q4	$25M	Buy	161,130 +1,419	+0.9%	+$207K	0.47%	33
2023 Q3	$23.8M	Buy	159,711 +4,626	+3%	+$679K	0.51%	31
2023 Q2	$20.9M	Buy	155,085 +1,871	+1%	+$274K	0.47%	35
2023 Q1	$24.4M	Sell	153,214 -1,226	-0.8%	-$187K	0.65%	26
2022 Q4	$25M	Buy	154,440 +12,997	+9%	+$1.99M	0.63%	29
2022 Q3	$19M	Sell	141,443 -3,929	-3%	-$564K	0.53%	34
2022 Q2	$22.3M	Sell	145,372 -3,505	-2%	-$536K	0.56%	31
2022 Q1	$24.1M	Buy	148,877 +18,298	+14%	+$2.66M	0.54%	30
2021 Q4	$17.7M	Buy	130,579 +2,473	+2%	+$292K	0.39%	47
2021 Q3	$13.8M	Buy	128,106 +3,966	+3%	+$453K	0.35%	49
2021 Q2	$14M	Buy	124,140 +8,008	+7%	+$902K	0.35%	52
2021 Q1	$12.6M	Buy	116,132 +6,439	+6%	+$689K	0.35%	56
2020 Q4	$11.8M	Sell	109,693 -4,710	-4%	-$453K	0.35%	56
2020 Q3	$10M	Buy	114,403 +21,677	+23%	+$2.04M	0.33%	67
2020 Q2	$9.1M	Buy	92,726 +7,251	+8%	+$638K	0.32%	67
2020 Q1	$6.51M	Buy	85,475 +4,070	+5%	+$347K	0.3%	75
2019 Q4	$7.21M	Sell	81,405 -4,206	-5%	-$349K	0.28%	73
2019 Q3	$6.48M	Buy	85,611 +13,786	+19%	+$945K	0.28%	74
2019 Q2	$5.22M	Buy	71,825 +1,778	+3%	+$140K	0.23%	89
2019 Q1	$5.64M	Sell	70,047 -167	-0.2%	-$13.7K	0.25%	81
2018 Q4	$6.47M	Sell	70,214 -3,988	-5%	-$351K	0.33%	58
2018 Q3	$7.02M	Sell	74,202 -8,038	-10%	-$762K	0.31%	61
2018 Q2	$7.62M	Sell	82,240 -1,025	-1%	-$100K	0.34%	58
2018 Q1	$7.88M	Buy	83,265 +4,086	+5%	+$449K	0.33%	56
2017 Q4	$7.66M	Buy	79,179 +1,117	+1%	+$105K	0.34%	56
2017 Q3	$6.94M	Buy	78,062 +11,457	+17%	+$872K	0.33%	64
2017 Q2	$4.83M	Sell	66,605 -1,919	-3%	-$129K	0.25%	90
2017 Q1	$4.46M	Buy	68,524 +3,435	+5%	+$216K	0.25%	86
2016 Q4	$4.08M	Buy	65,089 +17,544	+37%	+$1.07M	0.25%	91
2016 Q3	$3M	Buy	47,545 +7,689	+19%	+$498K	0.2%	100
2016 Q2	$2.47M	Buy	39,856 +9,540	+31%	+$581K	0.18%	112
2016 Q1	$1.73M	Sell	30,316 -5,828	-16%	-$325K	0.15%	126
2015 Q4	$2.14M	Sell	36,144 -743	-2%	-$42.8K	0.18%	102
2015 Q3	$2.01M	Buy	36,887 +4,781	+15%	+$311K	0.25%	82
2015 Q2	$2.16M	Sell	32,106 -6,602	-17%	-$431K	0.28%	78
2015 Q1	$2.27M	Buy	38,708 +14,029	+57%	+$848K	0.27%	76
2014 Q4	$1.61M	Buy	24,679 +3,410	+16%	+$215K	0.29%	87
2014 Q3	$1.23M	Buy	21,269 +151	+0.7%	+$8.38K	0.29%	82
2014 Q2	$1.2M	Buy	+21,118	New	+$1.11M	0.4%	74

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Stratos Wealth Partners's ABBV Position: Q1 2026 in Review

Stratos Wealth Partners reduced its AbbVie (ABBV) stake by 4.3% in Q1 2026, selling an estimated $1.7M and leaving 168,351 shares worth $36.6M. The position accounts for 0.42% of the portfolio, ranked #41.

Stratos Wealth Partners first reported a position in ABBV in Q2 2014 and has held it in 48 quarters since. The position peaked at $41.3M in Q3 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Stratos Wealth Partners held 168,351 shares of AbbVie worth $36.6M as of Q1 2026.
Stratos Wealth Partners sold 7,655 AbbVie shares in Q1 2026, an estimated $1.7M.
AbbVie made up 0.42% of Stratos Wealth Partners's portfolio in Q1 2026, its #41 holding.
Stratos Wealth Partners first reported a position in AbbVie in Q2 2014 and has held it in 48 quarters since.
Stratos Wealth Partners's AbbVie position peaked at $41.3M in Q3 2025.
4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Stratos Wealth Partners's 13F filing for Q1 2026, filed 28 Apr 2026.